$MGRX

Mangoceuticals' subsidiary MangoRx IP Holdings raised $2.5 million from two investors to commercialize its antiviral patent portfolio. The investment, paid in two tranches, gives investors a 25% stake in the subsidiary. The funds will support the development of MGX-0024, an antiviral technology with applications in animal and human health. The company's stock closed at $0.48 on Thursday, up 12.24%.

Mangoceuticals (MGRX) shares dropped 12.24% after hours to $0.42 following a $2.5M investment in its former subsidiary, MangoRx IP Holdings. The investment, not involving MGRX stock, aims to advance commercialization. The company's market cap is $10.32M, with shares down 78.06% over the past year.

MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuan

Mangoceuticals (MGRX) and Nuclea Energy mutually ended their business combination agreement on Aug 19, 2026, due to failing to secure $15 million in PIPE financing by the Aug 21 deadline. The termination is mutual, with no fees or breaches alleged.

MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Business Combination Agreement with Nuclea Energy Inc. On August 19, 2026, Mangoceuticals, Inc. (the “Company” or “MGRX”) and Nuclea Energy Inc. (“Nuclea”) mutually agreed to terminate that certain Business

Mangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trending on Thursday night. Shares of the public health and wellness company jumped 137.77% to $0.70 in after-hours trading on Thursday following the announcement of a definitive business combination with Nuclea Energy Inc., a developer of the Morpheus lead-cooled microreactor.

Mangoceuticals (NASDAQ: MGRX) said it signed a definitive business combination agreement with Nuclea Energy to take Nuclea’s Morpheus lead-cooled microreactor public. A new Mangoceuticals subsidiary will amalgamate with Nuclea, with Nuclea shareholders receiving exchangeable shares. Closing is subject to Mangoceuticals and Nasdaq approvals, with rights capped at 19.99% until then.

Nuclea Energy Inc. said it signed a definitive business combination agreement with Mangoceuticals, Inc. (NASDAQ: MGRX) to pursue a Nasdaq public listing for Nuclea. Nuclea shareholders will receive exchangeable shares tied to Mangoceuticals common stock, with former Nuclea holders owning about 96% and Mangoceuticals holders about 4% post-closing, subject to approvals and a 19.99% Nasdaq cap.

MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology Business Combination Agreement to Bring Nuclea’s Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Dema